208 Participants Needed

ORX142 for Healthy Adults

OC
Overseen ByORX142 Centessa Program Lead
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Centessa Pharmaceuticals (UK) Limited
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called ORX142, an experimental drug, to evaluate its safety and how the body processes it. It involves different groups of healthy adults, including those who are sleep-deprived, to understand the effects of single and multiple doses. Individuals who are generally healthy and free from major health issues, such as heart or sleep problems, are suitable candidates for this trial. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

Do I need to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that ORX142 is likely to be safe for humans?

Research has shown that ORX142 is under study to assess its safety and tolerability. So far, 89 healthy adults have taken ORX142, and researchers are examining its effects after single and multiple doses. These early trials test ORX142 on healthy individuals to ensure safety. This step is standard for new treatments to confirm they don't cause harm before testing on larger groups or those with the illness.

No specific information about side effects has been shared, which typically indicates that nothing unexpected or serious has been observed at this stage. It is important to note that ORX142 remains in the early testing phase, so ongoing studies are crucial to confirm its safety.12345

Why do researchers think this study treatment might be promising?

ORX142 is unique because it targets the brain's orexin system, which plays a key role in regulating wakefulness and alertness. Unlike current options that often work by promoting wakefulness through stimulating the central nervous system or modulating neurotransmitters like dopamine, ORX142 directly interacts with orexin receptors. This novel mechanism of action could provide a more precise way to manage symptoms related to sleep deprivation without the jittery side effects associated with typical stimulants. Researchers are particularly excited about its potential to deliver quick results, possibly offering relief in a matter of hours rather than days.

What evidence suggests that ORX142 could be effective?

Research has shown that ORX142, a drug targeting specific brain receptors, may improve alertness. In this trial, participants will receive ORX142 in various study parts, including evaluating its effects in healthy older adults, assessing food effects, and studying its impact on acutely sleep-deprived individuals. Studies have found that ORX142 helped people stay awake longer than those who took a placebo, a pill with no active ingredients. This drug works by activating certain brain receptors that control sleep and wakefulness. Early results suggest that ORX142 could help manage sleep deprivation, but further research is needed to confirm these findings.13467

Are You a Good Fit for This Trial?

This trial is for healthy adults aged 18 to 80 who experience excessive daytime sleepiness or hypersomnia. The detailed eligibility criteria are not provided, but typically participants should not have other significant health issues that could interfere with the study.

Inclusion Criteria

I am between 60 and 80 years old.
I am healthy as confirmed by recent medical exams.
I am between 18 and 55 years old.

Exclusion Criteria

I do not have major health issues in my heart, lungs, liver, kidneys, blood, hormones, brain, or mental health.
I have a condition that increases my risk of seizures.
I have a serious sleep problem, like insomnia or sleep apnea.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive single and multiple doses of ORX142 to evaluate safety, tolerability, and pharmacokinetics

Varies by part (e.g., single dose or multiple doses)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week

What Are the Treatments Tested in This Trial?

Interventions

  • ORX142
Trial Overview The study is testing ORX142 tablets compared to placebo tablets. It aims to understand how safe and tolerable ORX142 is, and how the body processes it after one dose and multiple doses over time.
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Group I: Part E: PoC Study in Acutely Sleep-deprived Healthy AdultsExperimental Treatment2 Interventions
Group II: Part D: Evaluation of a Single Dose in Healthy Older AdultsExperimental Treatment2 Interventions
Group III: Part C: MAD Study in Healthy AdultsExperimental Treatment2 Interventions
Group IV: Part B: Food-effect Evaluation in Healthy AdultsExperimental Treatment1 Intervention
Group V: Part A: SAD Study in Healthy AdultsExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Centessa Pharmaceuticals (UK) Limited

Lead Sponsor

Trials
2
Recruited
100+

Citations

A Study of ORX142 in Healthy Adult Subjects, Including ...Most clinical studies have one primary outcome measure, but some have more than one. ... The main reason for the clinical trial. The types of primary purpose are: ...
Release DetailsIn addition, ORX142 achieved statistically significant and dose-dependent improvements from baseline compared to placebo in mean sleep latency ...
Centessa receives FDA clearance to begin clinical trial ...Centessa Pharmaceuticals announced that the US FDA has cleared its investigational new drug (IND) application for ORX142, a novel orexin receptor 2 agonist.
Centessa to Advance Orexin Agonist ORX142 to Clinical ...The study is intended to evaluate efficacy, tolerability, and pharmacokinetics of ORX750, but will also include other efficacy outcomes, such as ...
Centessa Pharmaceuticals Announces Clearance of ...We are excited to begin executing our ORX142 Phase 1 clinical study in acutely sleep-deprived healthy volunteers which is aimed at generating ...
Release DetailsORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative ...
Press Release dated June 16, 2025We are excited to begin executing our ORX142 Phase 1 clinical study in acutely sleep-deprived healthy volunteers which is aimed at generating ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security